Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

PharmaEngine Inc

4162.TWO ✗ NOT COMPLIANT ☆ Track — members

Taipei Exchange · Healthcare · Biotechnology & Medical Research ·

Taiwan Micro Cap Analyst: HOLD

Last Close

$1.89

▲ +1.18%

Market Cap $274.36M · Vol 291.00K

Key Metrics

P/E Ratio

16.02

FWD: 5.98

Market Cap

$274.36M

Micro Cap

Div Yield

3.33%

Annual dividend

EPS Growth

+42.28%

YoY

RSI (14)

42.54

Momentum

Beta

0.26

vs Market

52W High

$2.34

21.23% below

52W Low

$1.67

11.89% above

Volume

291.00K

Avg 656.83K

P/B

2.05

Price-to-book

ROE

N/A

Return on equity

Free Float

62.68%

Public shares

Shariah Compliance8 STANDARDS

✗ PharmaEngine Inc (4162.TWO) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does 4162.TWO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.38%

-11.76%

+5.08%

-7.12%

YTD

-14.77%

-11.76%

-30.13%

+2.56%

Financials & Valuation

TTM · Annual

Total Revenue	$29.09M
Net Income	$12.37M
Revenue Growth (YoY)	+31.11%
Gross Margin	94.31%
Operating Margin	46.68%
Net Profit Margin	42.53%
ROE	N/A
ROA · ROIC	9.26% · 7.47%

P/E Ratio	16.02
Forward P/E (FY1)	5.98
PEG Ratio	-0.34
P/S	11.12
P/B	2.05
P/FCF	5.87
EPS Growth	+42.28%
Outstanding Shares	145.68M

Technical Indicators

50-Day SMA	$1.95
200-Day SMA	$2.00
RSI (14)	42.54
Beta	0.26
52-Week High	$2.34
52-Week Low	$1.67

Volume Today	291.00K
Avg Daily Volume (30D)	656.83K
Relative Volume	0.44x
Volatility (10D)	32.05
Volatility (30D)	35.75
Free Float	62.68%

Analyst Consensus

HOLD

Current Price $1.89

Mean Target N/A

52W Low$1.67 52W High$2.34

Current

Target

$1.67 $2.34

Current Analyst target

· 2 analysts

Identifiers

ExchangeTaipei Exchange

FIGIBBG0021164R7

ISINTW0004162003

CountryTaiwan

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateOct 28, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.09% ONC BeOne Medicines AG +1.44% RVMD Revolution Medicines Inc -1.07% 068270.KS Celltrion Inc -0.93% ABVX Abivax SA -2.75%

Company Profile

PharmaEngine Inc is a Taiwan-based company primarily engaged in new drug development. The main business is the research and development of various cancer drugs. ONIVYDE is a novel and stable encapsulated form of the marketed chemotherapy drug irinotecan in a long-circulating nanoliposome for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. It has received marketing approvals in Taiwan, the United States, the European Union, Singapore, South Korea, Japan, China and other regions. PEP07, a checkpoint kinase 1 (CHK1) inhibitor, which targets the deoxyribonucleic acid damage response (DDR) network, is in Phase 1 clinical trial stage and its target is to treat hematologic cancers such as acute myeloid leukemia (AML) and mantle cell lymphoma (MCL), and solid tumors.